Table 1 Baseline characteristics of 432 patients chronically infected with HCV, treated with peginterferon and ribavirin in Denmark between 1 January 2002 and 1 January 2007
Whole cohort | |||
|---|---|---|---|
SVR | Non-SVR | ||
Total | 274 | 158 | |
Gender | Male | 177 (64.5) | 105 (66.5) |
Nationality | European | 226 (82.5) | 146 (92.4) |
Non-European | 48 (17.5) | 12 (7.6) | |
Route of infection | IDU | 145 (52.9) | 74 (46.8) |
non-IDU | 37 (13.5) | 30 (19.0) | |
Unknown | 92 (33.6) | 54 (34.2) | |
Age at treatment initiation | ≤ 45 years | 148 (54.0) | 49 (31.0) |
Genotype | 1 | 59 (21.5) | 74 (46.8) |
2 | 37 (13.5) | 13 (8.2) | |
3 | 168 (61.3) | 67 (42.4) | |
4 | 6 (2.2) | 4 (2.5) | |
6 | 2 (0.7) | 0 | |
Unknown | 2 (0.7) | 0 | |
HCV-RNA | > 600.000 IU/mL | 92 (33.6) | 77 (48.7) |
Elevated ALT | 2 × UNL* | 149 (54.4) | 73 (46.2) |
Treating Department (speciality) | Infectious Diseases | 177 (64.6) | 101 (63.9) |
Gastroenterology/Hepatology | 97 (35.4) | 57 (36.1) | |
Liver biopsy within 3 years | Yes | 152 (55.5) | 98 (62.0) |
Treatment completion | As planned | 193 (70.4) | 65 (41.1) |
With dose reduction | 55 (20.1) | 43 (27.2) | |
Ended before scheduled | 24 (8.8) | 39 (24.7) | |
Unknown | 2 (0.7) | 11 (7.0) | |